Event
【GIR Open Seminar】 Dr. Wei-Li Hsu / National Chung-Hsing University (Taiwan)
| Date | 2025.1.22 (14：00 - 15：00) |
|---|---|
| Venue |
Lecture room L1113, 1st Fl. Building 11, Koganei campus, TUAT |
| Speaker | Dr. Wei-Li Hsu |
| Affiliation | National Chung-Hsing University (Taiwan) |
| Title | "Development of rapid diagnostic tests and theraputic antibody for SFTSV infection" ＜Abstract＞ Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne zoonotic disease caused by the SFTS virus (SFTSV). First identified in China in 2009, it has since spread across East Asia, including South Korea, Japan, and Taiwan. With a human fatality rate reaching 30%, effective vaccines or treatments are urgently needed. The glycoprotein Gn, a major surface antigen of SFTSV, is a promising target for the development of vaccines and therapeutic antibodies due to its ability to induce a strong humoral immune response. In this study, a series of monoclonal antibodies (mAbs) were generated, and their antigenic epitopes were characterized for potential application in diagnostics and therapeutics. Based on the epitope profile, four mAb targeting distinct epitopes were selected to develop an immunochromatographic test strip for the detection of SFTSV Gp antigen. This assay incorporated Gn1 mAb, recognizing N-terminal Gn, conjugated with magnetic beads to capture the antigen, with three other mAbs and anti-mouse antibodies coated to the test and control lines, respectively. The detection sensitivity of the strip reached an antigen detection limit as low as 10 ng per reaction. Of note, among the generated antibodies, Gn7 demonstrated potent neutralizing activity, achieving 90-100% neutralization with an IC50 of 1.1 µg/mL. Furthermore, Gn7 exhibited cross-neutralizing activity against two SFTSV genotypes currently circulating in Taiwan and Japan, with neutralization rates around 90% and IC50 values ranging from 0.6 to 6.7 µg/mL. To enhance its therapeutic potential, a chimeric Gn7 was generated by fusing the murine antibody's variable (Fab) regions with human constant (Fc) regions, thereby reducing the immunogenicity of mAb while retaining similar neutralizing efficacy. These results highlight Gn7 as a promising therapeutic candidate for SFTSV treatment, with future in vivo studies planned to evaluate its protective efficacy and therapeutic potential. Keywords: SFTSV, Gn, monoclonal antibody, lateral flow device, viral neutralization |
| Language | English |
| Intended for | Everyone is welcome to join. |
| Co-Organized by | Institute of Global Innovation Research ”LIFE SCIENCE” Kuroda Team Excellent Leader Development for Super Smart Society by New Industry Creation and Diversity |
| Contact | Institute of Global Innovation Research, Institute of Engineering Prof. Yutaka Kuroda e-mail: ykuroda ( at ) cc.tuat.ac.jp |
| Remarks | This seminar will only be held face-to-face. |
このページの上部へ